当前位置: X-MOL 学术Cardiovasc. Diabetol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies.
Cardiovascular Diabetology ( IF 8.5 ) Pub Date : 2019-11-13 , DOI: 10.1186/s12933-019-0958-2
Cristina Razquin 1, 2, 3 , Miguel Ruiz-Canela 1, 2, 3 , Clary B Clish 4 , Jun Li 5, 6 , Estefania Toledo 1, 2, 3 , Courtney Dennis 4 , Liming Liang 6, 7 , Albert Salas-Huetos 3, 8 , Kerry A Pierce 4 , Marta Guasch-Ferré 5, 8 , Dolores Corella 3, 9 , Emilio Ros 10 , Ramon Estruch 3, 11 , Enrique Gómez-Gracia 12 , Montse Fitó 3, 13 , Jose Lapetra 3, 14 , Dora Romaguera 3, 15 , Angel Alonso-Gómez 16 , Lluis Serra-Majem 3, 17 , Jordi Salas-Salvadó 3, 8 , Frank B Hu 5, 18 , Miguel A Martínez-González 1, 2, 3, 5
Affiliation  

BACKGROUND The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D or CVD in the PREDIMED trial; (b) the effect of the dietary intervention on 1-year changes in these metabolites, and (c) whether the Mediterranean diet (MedDiet) interventions can modify the effects of these metabolites on CVD or T2D risk. METHODS Two unstratified case-cohort studies nested within the PREDIMED trial were used. For CVD analyses, we selected 696 non-cases and 221 incident CVD cases; for T2D, we included 610 non-cases and 243 type 2 diabetes incident cases. Metabolites were quantified using liquid chromatography-tandem mass spectrometry, at baseline and after 1-year of intervention. RESULTS In weighted Cox regression models, we found that baseline lysine (HR+1 SD increase = 1.26; 95% CI 1.06-1.51) and 2-AAA (HR+1 SD increase = 1.28; 95% CI 1.05-1.55) were both associated with a higher risk of T2D, but not with CVD. A significant interaction (p = 0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have a significant effect on 1-year changes of the metabolites. CONCLUSIONS Our results provide an independent prospective replication of the association of 2-AAA with future risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes-dependent. No evidence of effects of MedDiet intervention on lysine, 2-AAA or pipecolic acid changes was found. Trial registration ISRCTN35739639; registration date: 05/10/2005; recruitment start date 01/10/2003.

中文翻译:

PREDIMED研究中的赖氨酸途径代谢产物和2型糖尿病和心血管疾病的风险:两项个案研究的结果。

背景技术心血管疾病(CVD)和2型糖尿病(T2D)的大流行需要鉴定新的预测生物标志物。可能随着生活方式的改变而可能改变的生物标记值得特别关注。我们的目的是分析:(a)在PREDIMED试验中,赖氨酸,2-氨基己二酸(2-AAA)或胡椒酸与T2D或CVD风险的关系;(b)饮食干预对这些代谢物1年变化的影响,以及(c)地中海饮食(MedDiet)干预是否可以改变这些代谢物对CVD或T2D风险的影响。方法使用了两个嵌套在PREDIMED试验中的未分层病例队列研究。对于CVD分析,我们选择了696个非案例和221个入射CVD案例。对于T2D,我们包括610例非病例和243例2型糖尿病事件。在基线和干预1年后,使用液相色谱-串联质谱法对代谢产物进行定量。结果在加权Cox回归模型中,我们发现基线赖氨酸(HR + 1 SD增加= 1.26; 95%CI 1.06-1.51)和2-AAA(HR + 1 SD增加= 1.28; 95%CI 1.05-1.55)都是与罹患T2D的风险较高有关,但与CVD无关。观察到基线赖氨酸和T2D在CVD风险上存在显着的相互作用(p = 0.032):患有普遍的T2D和高水平的赖氨酸的受试者表现出最高的CVD风险。MedDiet的干预措施对代谢物的1年变化没有显着影响。结论我们的结果对2-AAA与未来T2D风险的关联提供了独立的前瞻性复制。我们发现赖氨酸与随后的CVD风险相关,这显然是糖尿病依赖性的。没有发现MedDiet干预对赖氨酸,2-AAA或胡椒酸变化有影响的证据。试用注册ISRCTN35739639;注册日期:2005年5月10日;招聘开始日期2003年1月10日。
更新日期:2019-11-13
down
wechat
bug